New horizons in sickle cell crisis treatment
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242249Keywords:
Clinical manifestation, Novel therapy, Pathogenesis, Pain crisis, Sickle cell crisis, sickle cell diseaseAbstract
Even if life expectancy has increased, sickle cell disease (SCD) still presents difficulties, especially because of the painful episodes that occur frequently and without warning, known as Vaso-occlusive crises (VOCs). These crises are brought on by different cells adhering to one another and obstructing tiny blood veins, which can cause excruciating agony and eventually harm organs and tissues. While the majority of current treatments concentrate on symptom management and pain relief with the use of medications, hydration, and other general approaches, new discoveries about the fundamental mechanisms of VOCs provide intriguing new therapeutic options. With the goal of precisely addressing the pathways causing inflammation and cell adhesion, these cutting-edge treatments may lessen the frequency of VOCs and shield vital organs from harm. Though these treatments provide hope for improved SCD management, careful assessment and analysis of their efficacy and accessibility are necessary to guarantee their general benefit.
Metrics
References
Osunkwo I, Manwani D, Kanter J. Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease. Ther Adv Hematol. 2020;11:204062072095500.
Hiran S. Multiorgan dysfunction syndrome in sickle cell disease. J Assoc Physicians. 2005;53:19–22.
Jang T. Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events. J Trans Med. 2021;19:397.
Allali S, Maciel TT, Hermine O, Montalembert M. Innate immune cells, major protagonists of sickle cell disease pathophysiology. Haematologica. 2020; 105:273-83.
Yousef, A. Acute chest syndrome in pediatric sickle cell disease: A 19-year tertiary center experience. Ann Thorac Med. 2022;17:199.
Aubry A, Paternot A, Vieillard-Baron A. Cœur pulmonaire. Rev Mal Respir. 2020;37:257-66.
Brousse V, Buffet P, Rees D. The spleen and sickle cell disease: the sick(led) spleen. Br J Haematol. 2014;166:165–176.
Brousse V. Acute splenic sequestration crisis in sickle cell disease: cohort study of 190 paediatric patients. Br J Haematol. 2012;156:643-8.
Yates AM, Hankins JS, Mortier NA, Aygun B, Ware RE. Simultaneous acute splenic sequestration and transient aplastic crisis in children with sickle cell disease. Pediatr Blood Cancer. 2009;53:479-81.
Tharaux PL. Endothelin in Renal Injury due to Sickle Cell Disease. 2011:185–199.
Bissonnette MLZ, Henriksen KJ, Delaney K, Stankus N Chang A. Medullary Microvascular Thrombosis and Injury in Sickle Hemoglobin C Disease. J Amr S Nephr. 2016;27:1300–1304 (2016).
Aggeli C. Stroke and presence of patent foramen ovale in sickle cell disease. J Thromb Thrombolysis. 2021;52:889-97.
Lim SH, Fast L, Morris A. Sickle cell vaso-occlusive crisis: it is a gut feeling. J Transl Med. 14, 334 (2016).
Gautam G, Harmon R, Foley R. Gastrointestinal vaso-occlusive crisis in sickle cell disease. Baylor University Medical Center Proceedings. 2022;35:856-7.
Praharaj, D. L. & Anand, A. C. Sickle Hepatopathy. J Clin Exp Hepatol. 2021;11:82-96.
Ferreira TFA. Chronic osteo-articular changes in patients with sickle cell disease. Advances in Rheumatology 61, 11 (2021).
Alagbe AE, Olaniyi JA, Aworanti OW. Adult sickle cell anaemia patients in bone pain crisis have elevated pro-inflammatory cytokines. Mediterr J Hematol Infect Dis. 2018;10:17.
Ahuja G. Priapism and sickle cell disease: special considerations in etiology, management, and prevention. Urol. 2021;156:40-7.
Vinnes EW, Lillemoen PK, Klingenberg O, Fjeld B, Iversen PO et al. Sickle cell disease – clinical manifestations and diagnostics.2023. Avialable at https://tidsskriftet.no/2023/02/kliniskoversikt/sigdcellesykdom-kliniske-manifestasjoner-og-diagnostikk.
Jang T. Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events. J Transl Med. 2021;19:397.
Howard J, Hemmaway J, Telfer P, Porter J, Layton DM, Awogbade M et al. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease. Blood. 2019;133(17):1865-75.
Field JJ. Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. 2017;1:1645-9.
Osunkwo I, Manwani D, Kanter J. Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease. Ther Adv Hematol. 2020;11:204062072095500.
Hoppe C. Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. Br J Haematol. 2017;177:620-9.
Ribeiro-Filho, J. et al. An evaluation of ticagrelor for the treatment of sickle cell anemia. Expert Rev Hematol. 202;13:1047-55.
Ataga KI. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. New. N Engl J Med. 2017;376:429-9.
Adashi EY, Gruppuso, PA, Cohen IG. CRISPR Therapy of Sickle Cell Disease: The Dawning of the Gene Editing Era. Am J Med. 2024;137(5):390-2.
Osunkwo I, Manwani D, Kanter J. Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease. Ther Adv Hematol. 2020;11:2040620720955000.
Downloads
Published
How to Cite
Issue
Section
